Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (DE:5Y6)
FRANKFURT:5Y6
Holding DE:5Y6?
Track your performance easily
5Y6 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.08 - €11.70
Previous Close€4.42
Volume236.00
Average Volume (3M)259.00
Market Cap
€290.79M
Enterprise Value€157.51M
Total Cash (Recent Filing)$143.21M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Feb 26, 2025EPS Estimate
-€0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding68,390,000
10 Day Avg. Volume66
30 Day Avg. Volume259
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-4.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
€21.37Price Target Upside383.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
COMPASS Pathways News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCOMP360 appears on track for a positive outcome from its Phase 3 program in treatment-resistant depression.
Market PositioningCOMPASS is seen as a pioneer in the psychedelics drug development field, with management making strategic moves to enhance the success probability in treating depression.
Stock RecommendationThe pullback on the shares is seen as a particularly good opportunity to BUY the stock.
Bears Say
Financial PerformanceA delay in timeline results in an unfortunate restructuring/more careful planning around cash and is disappointing for investors.
Stock PerformanceShares are down ~22% following the announcement of delays to the data readout for the P3 program.
Workforce ReductionManagement plans to reduce the workforce by ~30% to focus resources on execution of the P3 program.
---
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €4.08 and its highest was €11.70 in the past 12 months.
What is COMPASS Pathways’s market cap?
Currently, no data Available
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Oct 31, 2024. The company reported -€0.528 earnings per share for the quarter, beating the consensus estimate of -€0.538 by €0.009.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -€0.59.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 68,420,815 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€0.528 in its last earnings report, beating expectations of -€0.538. Following the earnings report the stock price went down -27.143%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Among the largest hedge funds holding COMPASS Pathways’s share is ARK Investment Management LLC. It holds COMPASS Pathways’s shares valued at 13M.
---
COMPASS Pathways Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.37 (383.58% Upside)
€21.37 (383.58% Upside)
Blogger Sentiment
Bullish
DE:5Y6 Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $16.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.67%
12-Months-Change
Fundamentals
Return on Equity
-64.99%
Trailing 12-Months
Asset Growth
-17.29%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
5Y6 Earnings Call
Q3 2024
0:00 / 0:00
---
5Y6 Stock 12 Month Forecast
Average Price Target
€21.37
▲(383.58% Upside)
Technical Analysis
COMPASS Pathways
―
Mind Medicine
―
ATAI Life Sciences
―
Relmada Therapeutics
―
Cybin
―
Best Analysts Covering 5Y6
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-35.55%
reiterated a buy rating 8 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -35.55% per trade.
---